Sign in

Chetan Shenoy

@cshenoy.bsky.social
842 followers 444 following 58 posts

Cardiologist and researcher, in cardiovascular magnetic resonance imaging, at the University of Minnesota

PostsRepliesMedia
Chetan Shenoy @cshenoy.bsky.social · 05/04/2026
In science, successful replication is the ultimate quality check! This is a highlight for our research group—David Birnie's group (one of the biggest names in cardiac sarcoidosis) just independently replicated our CMR phenotyping work! doi.org/10.1093/ehji... #EHJIMP #CardioSky #sarcoidosis
This study confirms, for the first time in a fully prospective cohort, the prognostic importance of CMR phenotyping in cardiac sarcoidosis. The high-risk CMR phenotype had 100% NPV, indicating the absence of VA events among patients without the high-risk phenotype. LGE phenotyping showed much higher interobserver reproducibility than LGE quantification and was five-fold faster.
2103
Reposted by Chetan Shenoy
Lars Mølgaard Saxhaug @load-dependent.eurosky.social · 01/04/2026
Related: you’ve definitely made me more conscious about not calling something «ischemic cardiomyopathy» just because there is coronary disease as it might just be a bistander.
011
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 01/04/2026
🧵 Are OCT and CMR really "complementary" in MINOCA? Or are they telling us conflicting stories? Reynolds et al (Circulation 2026) combined both modalities in 284 MINOCA patients. The results raise more questions than answers. 📄 www.ahajournals.org/doi/abs/10.1... 1/7
ahajournals.org
American Heart Association Journals
222
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
Have you ever wondered whether your patient with CAD and cardiomyopathy truly has ischemic cardiomyopathy, or whether the CAD is a “bystander”? You might be interested in our paper now out in Circulation #simultaneouspublication #AHA23 #cardiosky #Medsky #WhyCMR
2115
Chetan Shenoy @cshenoy.bsky.social · 06/10/2025
academic.oup.com/eurheartj/ad... #CardioSky #WhyCMR #Medsky
Response to a Letter to the Editor in Response to the Original Article "Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement" published in the European Heart Journal.
Response to a Letter to the Editor in Response to the Original Article "Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement" published in the European Heart Journal.
042
Reposted by Chetan Shenoy
Michael Hadley @hadleymd.bsky.social · 01/10/2025
Important multicenter study in #EHJ #CMR outperforms societal recs for ICD placement in cardiac sarcoidosis 📈AUC=0.86 for 5-yr risk of fatal/life-threatening arrhythmias ⚡Highest risk = abnl LVEF + LGE that is multifocal, septal, subepicardial, or involves RV freewall buff.ly/Nc2upbU #cardiotwitter
382
Reposted by Chetan Shenoy
Kardioklick @kardioklick.bsky.social · 19/07/2025
Must-watch lecture on cardiomyopathy and CMR by @cshenoy.bsky.social „more often than what is the EF we should ask the why?“ youtube.com/live/9or85hk...
youtube.com
Identifying the Cause of Cardiomyopathy Using CMR (Chetan Shenoy, MBBS, MS)
YouTube video by Houston Methodist DeBakey CV Education
274
Reposted by Chetan Shenoy
TCTMD @tctmd.bsky.social · 19/06/2025
“CMR phenotyping can be used immediately in clinical practice to identify patients with suspected cardiac sarcoidosis who would benefit from a primary prevention ICD," said Chetan Shenoy, MD. Read more about how this can prevent life-threatening ventricular arrhythmias: www.tctmd.com/news/cmr-may...
tctmd.com
CMR May Improve Assessment of ICD Need in Cardiac Sarcoidosis
The imaging was better than societal recommendations at discriminating long-term risk of ventricular arrhythmias.
112
Chetan Shenoy @cshenoy.bsky.social · 11/06/2025
Thank you, @toddneale.bsky.social, for your excellent reporting on our EHJ paper! @tctmd.bsky.social @escardio.bsky.social @paragbawaskar.bsky.social
361
Reposted by Chetan Shenoy
Pablo Perez Lopez @pabloplopez.bsky.social · 10/06/2025
#EHJCVI 🫀 What's the value of ventricular strain in systemic sclerosis? 📉 Both LVGLS and RVGLS are linked to death or MACE, unlike LVEF and RVEF 🧠 How does strain compare to traditional prognostic markers? 🔍 Read more 👉 doi.org/10.1093/ehjc... #CardioSky @jgrapsa.bsky.social @escardio.bsky.social
013
Chetan Shenoy @cshenoy.bsky.social · 27/05/2025
Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs. societal recommendations for implantable cardioverter-defibrillator placement academic.oup.com/eurheartj/ad... #Cardiosky #WhyCMR #Epeeps #Medsky
In patients with suspected cardiac sarcoidosis, CMR phenotyping showed greater discriminative accuracy than societal recommendations for predicting fatal or life-threatening ventricular arrhythmias, suggesting that it may be more effective at identifying candidates for primary prevention ICDs.
041
Reposted by Chetan Shenoy
Kardioklick @kardioklick.bsky.social · 25/05/2025
Cardiac sarcoidosis is a undervalued disease and difficult to diagnose and treat, considering potential life-threatening arrhythmias. Nice to have some more guidance. #cardiosky.
011
Chetan Shenoy @cshenoy.bsky.social · 24/05/2025
academic.oup.com/eurheartj/ad... @escardio.bsky.social #Cardiosky #WhyCMR #Epeeps #Medsky Please DM me if you would like a full-text PDF of the paper!
4106
Chetan Shenoy @cshenoy.bsky.social · 23/04/2025
pmc.ncbi.nlm.nih.gov/articles/PMC... #HCM #CardioSky #Cardiomyopathy
pmc.ncbi.nlm.nih.gov
Comparisons against baseline within randomised groups are often used and can be highly misleading
In randomised trials, rather than comparing randomised groups directly some researchers carry out a significance test comparing a baseline with a final measurement separately in each group. We give se...
023
Reposted by Chetan Shenoy
Chetan Shenoy @cshenoy.bsky.social · 21/03/2025
In patients with suspected cardiac sarcoidosis, cardiac FDG-PET is recommended after a normal CMR if there is a high clinical suspicion. What are the data supporting this recommendation? #CardioSky #MedSky #Sarcoidosis
2106
Reposted by Chetan Shenoy
Martin Ugander @mugander.bsky.social · 23/03/2025
Query sarcoid, normal #WhyCMR, so then should we do FDG-PET? Not much benefit.
052
Chetan Shenoy @cshenoy.bsky.social · 21/03/2025
In patients with suspected cardiac sarcoidosis, cardiac FDG-PET is recommended after a normal CMR if there is a high clinical suspicion. What are the data supporting this recommendation? #CardioSky #MedSky #Sarcoidosis
2106
Chetan Shenoy @cshenoy.bsky.social · 23/01/2025
This paper reports the coexistence of cardiac sarcoidosis and arrhythmogenic cardiomyopathy in 5 patients. heart.bmj.com/content/earl... #CardioSky #MedSky
heart.bmj.com
Coexistence of cardiac sarcoidosis and arrhythmogenic cardiomyopathy-associated genetic variants: a multicentre case-control study
Background Cardiac sarcoidosis (CS) is a chronic inflammatory disease characterised by non-caseating granulomas, while arrhythmogenic cardiomyopathy (ACM) is a genetic condition mainly affecting desmo...
153
Chetan Shenoy @cshenoy.bsky.social · 05/01/2025
Examples of study patients with serial CMR images. 

Patient A had resolution of LV thrombus on the first serial CMR done 64 days after the index CMR, and no recurrence was noted on subsequent serial CMRs done 688 and 1043 days after the index CMR. 
Patient B had no resolution of LV thrombus on serial CMRs done 591, 966, and 3555 days after the index CMR. 

Patient C had resolution of LV thrombus on the first serial CMR done 86 days after the index CMR; however, a new LV thrombus was identified on the second serial CMR done 401 days after the index CMR, which had resolved again by the third serial CMR done 1336 days after the index CMR.
196
Chetan Shenoy @cshenoy.bsky.social · 05/01/2025
Short-Axis LGE Images Showing Similar Septal Midmyocardial LGE in Viral Myocarditis and Genetic Cardiomyopathy.

(A) A patient with endomyocardial biopsy-proven parvovirus B19 myocarditis. Reproduced with permission from Greulich et al.

(B) A patient with cardiomyopathy and likely pathogenic variants in the desmin (DES) and transforming growth factor β 3 (TGFB3) genes. 

(C) A patient with cardiomyopathy and a pathogenic variant in the desmoplakin (DSP) gene. 

(D) A patient with cardiomyopathy and a pathogenic variant in the filamin C (FLNC) gene. 

(E) A patient with cardiomyopathy and a pathogenic variant in the lamin A/C (LMNA) gene. 

(F) A patient with cardiomyopathy and a pathogenic variant in the titin (TTN) gene.
132
Reposted by Chetan Shenoy
Sarah Hudson @sarahhudsonuk.bsky.social · 21/11/2024
Great thread on LV thrombus and embolism risk - especially if RWMA I discuss lifelong anti coagulation with my pts even if it looks resolved on echo, good to have some data to help back this up 👇
2156
Chetan Shenoy @cshenoy.bsky.social · 17/11/2024
Amazing achievement by rising star and post-doc in my lab @paragbawaskar.bsky.social, winner of the prestigious 2024 Melvin Judkins Early Career Investigator Award at #AHA24!! Congratulations!!! @ahascience.bsky.social
1154
Reposted by Chetan Shenoy
Lars Mølgaard Saxhaug @load-dependent.eurosky.social · 13/11/2024
It’s great that journals are coming over here, but what I have really missed after my departure from Twitter 2 years ago is this, the authors themselves presenting their works and discussing it with peers. #cardiosky #medsky #emimcc
2317
Reposted by Chetan Shenoy
Luke Cieslik 🇺🇦 @lukekc.bsky.social · 13/11/2024
With the big caveat that obvious alternative causes are not present such as AF.
131
Reposted by Chetan Shenoy
Luke Cieslik 🇺🇦 @lukekc.bsky.social · 13/11/2024
All patients with stroke is unrealistic in terms of cost, access and resourcing. However in patients with ischaemic stroke, LV dysfunction and/or recent MI I agree (if #echofirst + contrast is negative for thrombus).
141
Reposted by Chetan Shenoy
Luke Cieslik 🇺🇦 @lukekc.bsky.social · 13/11/2024
Thanks for your insights. Fascinating area.
011
Reposted by Chetan Shenoy
Luke Cieslik 🇺🇦 @lukekc.bsky.social · 13/11/2024
Thanks. So for example - post anterior infarct, persisting WMA on CMR at 6 months despite OMT (but improvement in overall LVEF). Lifelong anticoagulation or would you reimage at a further interval (I.e. 12 months) to look for improvement in wall motion abnormality?
121
Reposted by Chetan Shenoy
Luke Cieslik 🇺🇦 @lukekc.bsky.social · 13/11/2024
Great work Chetan. An important area where as a community we need to get better at managing - particularly in the post (anterior) STEMI space. What are your thoughts on stopping anticoagulation at 3 or 6 months post MI with persisting wall motion defects but resolved thrombus?
121
Reposted by Chetan Shenoy
Florian Zores @fzores.eurosky.social · 13/11/2024
Congratulations for this work! Do you have data for patients with CMR and echo to evaluate the discrepancy? We need a well designed RCT to answer this important although infrequent question. And to assess the effectiveness of DOAC in these cases
121
Chetan Shenoy @cshenoy.bsky.social · 12/11/2024
In 2019, we wrote a paper showing that patients with left ventricular thrombus have a long-term risk of embolism, extending to at least 8 years. We were puzzled by the finding… #CardioSky www.ahajournals.org/doi/10.1161/...
Figure 2 from the paper. Incidence of embolism in left ventricular (LV) thrombus patients compared with matched non-LV thrombus patients. Kaplan-Meier curves demonstrate the cumulative incidence of the composite embolic end point in the LV thrombus (in red) and in the matched non-LV thrombus (in blue) groups. Note the significant difference in the cumulative incidence of embolic events between the 2 groups.
32416
Reposted by Chetan Shenoy
Darren Dahly @statsepi.bsky.social · 10/10/2024
It depends!
2306
Chetan Shenoy @cshenoy.bsky.social · 19/10/2024
Read our editorial on avoiding errors when diagnosing myocarditis using CMR: www.sciencedirect.com/science/arti... @paragbawaskar.bsky.social #CardioSky
036
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
Finally, many thanks to @cshenoy.bsky.social for his mentorship, our outstanding team for their contributions, and the editors and reviewers at Circulation for all their efforts to make our paper better!
021
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
Read our paper here –https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.123.067032 And if you will be at #AHA23, come visit the poster session on Monday, Nov 13, 10:00-11.30 am, Zone 2. eppro01.ativ.me/src/EventPil...
131
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
An important trial related to this topic was just funded in the UK – Peter Swoboda at the University of Leeds is the PI of an RCT to identify the best initial test for newly diagnosed HF… we look forward to the results of CROSS-HF in a few years.
121
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
And if NICM and dualCM do influence outcomes, the next trial should investigate whether the routine use of CMR to identify the cause of cardiomyopathy improves the selection of patients for coronary revascularization, and overall long-term outcomes.
121
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
We need to investigate whether NICM or dualCM in patients with CAD influences outcomes after coronary revascularization. An ancillary study of the STICH3C trial by Mario Gaudino and Jonathan Weinsaft at Cornell will give us some answers in about 5 years.
121
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
So what? Patients with CAD+NICM or dualCM should be treated with a statin, aspirin, and guideline-directed HF therapy the same as those with CAD+ICM. But do patients with CAD+ NICM or dualCM benefit from coronary revascularization in the same manner as those with CAD+ICM?
121
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
Prior studies have found better outcomes for NICM vs. ICM. What explains worse outcomes for NICM in our study? We can only speculate, but it may be because patients in our study had 2-3 diseases – CAD+NICM… or CAD+ICM+NICM. Prior studies compared NICM without CAD to ICM+CAD.
121
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
And we looked at their long-term outcomes. Patients with CAD+NICM or dualCM had a greater risk of all-cause death or heart failure hospitalization, all-cause death, and heart failure hospitalization compared with CAD+ICM. The risk of CV death was not different.
121
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
We found NICM or dualCM in 1 of every 6 patients with CAD. CAD+NoCM - 18.2% CAD+ICM - 64.8% CAD+NICM - 9.3% CAD+dualCM - 7.7% The prevalence of CAD+NICM or dualCM was 16.9% or 1 in 6 patients with CAD.
121
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
We looked at their CMRs and coronary angiography data and classified them into one of: 1. No cardiomyopathy (CAD+NoCM) – normal LVEF and no LGE 2. Ischemic cardiomyopathy (CAD+ICM) 3. Non-ischemic cardiomyopathy (CAD+NICM) 4. Dual cardiomyopathy (CAD+dualCM) – both ICM and NICM
121
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
We did a large retrospective observational study of 3,023 patients with obstructive CAD who had CMR for any clinical indication at our health system.
121
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
So how often do patients with CAD have NICM or dual (both ICM and NICM) cardiomyopathy? How do these patients do compared to patients with ICM? We tried to answer these questions.
121
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
There has been interest in this topic of late because trials of coronary revascularization other than STICHES have not shown revascularization to be beneficial.
121
Reposted by Chetan Shenoy
Parag Bawaskar @paragbawaskar.bsky.social · 11/11/2023
Currently, we determine the cause of cardiomyopathy based on coronary angiography findings… CAD=ICM; No CAD=NICM However, pathology and small CMR studies have shown that NICM can occur with “bystander” CAD ICM can occur without CAD Both ICM and NICM can occur together
131
Chetan Shenoy @cshenoy.bsky.social · 11/11/2023
A thread about our latest paper from star post-doc @paragbawaskar.bsky.social 👇
050